MX2022006132A - Anticuerpos anti alfa-v beta-6 (avb6) y conjugados de anticuerpo-farmaco. - Google Patents
Anticuerpos anti alfa-v beta-6 (avb6) y conjugados de anticuerpo-farmaco.Info
- Publication number
- MX2022006132A MX2022006132A MX2022006132A MX2022006132A MX2022006132A MX 2022006132 A MX2022006132 A MX 2022006132A MX 2022006132 A MX2022006132 A MX 2022006132A MX 2022006132 A MX2022006132 A MX 2022006132A MX 2022006132 A MX2022006132 A MX 2022006132A
- Authority
- MX
- Mexico
- Prior art keywords
- antibodies
- antibody
- drug conjugates
- avb6
- avß6
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962943959P | 2019-12-05 | 2019-12-05 | |
| US202063012584P | 2020-04-20 | 2020-04-20 | |
| PCT/US2020/063390 WO2021113697A1 (en) | 2019-12-05 | 2020-12-04 | Anti-avb6 antibodies and antibody-drug conjugates |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022006132A true MX2022006132A (es) | 2022-06-17 |
Family
ID=76222033
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022006132A MX2022006132A (es) | 2019-12-05 | 2020-12-04 | Anticuerpos anti alfa-v beta-6 (avb6) y conjugados de anticuerpo-farmaco. |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US11827709B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4069297A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7551750B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220110231A (cg-RX-API-DMAC7.html) |
| CN (1) | CN114828887B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020397070A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022009570A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3159414A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL293195A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022006132A (cg-RX-API-DMAC7.html) |
| TW (2) | TWI884192B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021113697A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI884192B (zh) | 2019-12-05 | 2025-05-21 | 美商西健公司 | 抗αVβ6抗體及抗體-藥物結合物 |
| JP2024510435A (ja) | 2021-03-18 | 2024-03-07 | シージェン インコーポレイテッド | 生体活性化合物の内部移行複合体からの選択的薬物放出 |
| TW202417057A (zh) * | 2022-10-26 | 2024-05-01 | 大陸商同潤生物醫藥(上海)有限公司 | 人源化的l1cam抗體藥物偶聯物 |
| JP2025537099A (ja) | 2022-11-03 | 2025-11-14 | シージェン インコーポレイテッド | 抗αVβ6抗体および抗体-薬物コンジュゲートならびにがんの治療におけるそれらの使用 |
| WO2024129756A1 (en) | 2022-12-13 | 2024-06-20 | Seagen Inc. | Site-specific engineered cysteine antibody drug conjugates |
| WO2024263932A2 (en) | 2023-06-23 | 2024-12-26 | Mythic Therapeutics, Inc. | Itgb6-binding proteins and uses thereof |
| WO2025064435A1 (en) * | 2023-09-19 | 2025-03-27 | Imaginab, Inc. | Antigen binding constructs directed to integrin αvβ6 |
| WO2026011013A1 (en) | 2024-07-02 | 2026-01-08 | Epibiologics, Inc. | Binding agents and uses thereof |
| WO2026112478A1 (en) | 2024-11-24 | 2026-05-28 | Mythic Therapeutics, Inc. | Lrrc15-binding proteins, multispecific anti-lrrc15 x anti-tumor-associated antigen (taa) antibodies, conjugation linkers, and methods of use and production thereof |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5962643A (en) | 1991-07-11 | 1999-10-05 | The Regents Of The University Of California | Integrin β subunit and uses thereof |
| NZ502546A (en) | 1997-08-08 | 2002-02-01 | Univ California | Treatment of acute lung injury and fibrosis with antibodies to alpha-v-beta-6 |
| US6160099A (en) * | 1998-11-24 | 2000-12-12 | Jonak; Zdenka Ludmila | Anti-human αv β3 and αv β5 antibodies |
| AU2002258808A1 (en) | 2001-04-30 | 2002-11-11 | Eli Lilly And Company | Humanized antibodies |
| MY147019A (en) | 2002-03-13 | 2012-10-15 | Biogen Idec Inc | Anti-alpha v beta 6 antibodies |
| WO2003087340A2 (en) | 2002-04-12 | 2003-10-23 | Raven Biotechnologies, Inc. | Antibodies that bind to integrin alpha-v-beta-6 and methods of use thereof |
| US7241598B2 (en) | 2004-06-29 | 2007-07-10 | The Chinese University Of Hong Kong | Frame-shifting PCR for germline immunoglobulin genes retrieval and antibody engineering |
| EA200700751A1 (ru) | 2004-10-05 | 2008-06-30 | Элан Фарма Интернэшнл Лимитед | Способы и композиции для улучшения продуцирования рекомбинантного белка |
| EP2322560B1 (en) | 2005-03-10 | 2013-09-04 | Morphotek, Inc. | Anti-mesothelin antibodies |
| EP1883424A2 (en) | 2005-05-18 | 2008-02-06 | Biogen Idec Inc. | Methods for treating fibrotic conditions |
| CN102875681A (zh) | 2005-07-08 | 2013-01-16 | 拜奥根Idec马萨诸塞公司 | 抗-αvβ6抗体及其用途 |
| KR20080039969A (ko) | 2005-08-31 | 2008-05-07 | 노보 노르디스크 헬스 케어 악티엔게젤샤프트 | Gla 도메인을 결합하는 인간 fvii 단일클론의 항체및 이것의 사용 |
| BRPI0714381A2 (pt) | 2006-07-10 | 2013-03-05 | Biogen Idec Inc | composiÇÕes e mÉtodos para inibir crescimento de cÂnceres deficientes em smad4 |
| WO2008112004A2 (en) | 2006-08-03 | 2008-09-18 | Astrazeneca Ab | ANTIBODIES DIRECTED TO αVβ6 AND USES THEREOF |
| JP2010506944A (ja) | 2006-10-19 | 2010-03-04 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | インテグリンαVβ6のアンタゴニストを用いる慢性喘息の処置および予防 |
| CL2008001071A1 (es) * | 2007-04-17 | 2009-05-22 | Smithkline Beecham Corp | Metodo para obtener anticuerpo penta-especifico contra il-8/cxcl8, gro-alfa/cxcl1, gro-beta/cxcl2), gro-gama/cxcl3 y ena-78/cxcl5 humanas; anticuerpo penta-especifico; proceso de produccion del mismo; vector, hbridoma o celela que lo comprende; composicion farmceutica; uso para tratar copd, otras enfermedades. |
| AU2009203464A1 (en) | 2008-01-11 | 2009-07-16 | Forerunner Pharma Research Co., Ltd. | Anti-CLDN6 antibody |
| CN101959929B (zh) | 2008-03-27 | 2013-05-01 | 泰尔茂株式会社 | 生物体吸收性材料及使用其的生物体内留置物 |
| AU2009245724A1 (en) | 2008-05-09 | 2009-11-12 | Ablynx N.V. | Amino acid sequences directed against integrins and uses thereof |
| BR112012003686B1 (pt) * | 2009-08-19 | 2021-09-21 | Merck Patent Gmbh | Anticorpos monoclonais, seu uso para detecção de complexos de integrina em material ffpe, e polinucleotídeo |
| WO2011046309A2 (en) | 2009-10-12 | 2011-04-21 | Korea Research Institute Of Bioscience And Biotechnology | A diagnostic marker for hepatocellular carcinoma comprising anti-fasn autoantibodies and a diagnostic composition for hepatocellular carcinoma comprising antigens thereof |
| MX361929B (es) * | 2010-11-19 | 2018-12-19 | Eisai R&D Man Co Ltd Star | Anticuerpos anti-ligando de quimiocina cc 20 (ccl20) neutralizantes. |
| CN105017420B (zh) * | 2012-02-17 | 2019-05-28 | 西雅图基因公司 | 针对整联蛋白αvβ6的抗体和使用该抗体治疗癌症 |
| US20150086570A1 (en) | 2012-03-29 | 2015-03-26 | Biogen Idec Ma Inc. | Biomarkers for use in integrin therapy applications |
| US10035859B2 (en) * | 2013-03-15 | 2018-07-31 | Biogen Ma Inc. | Anti-alpha V beta 6 antibodies and uses thereof |
| WO2014143739A2 (en) * | 2013-03-15 | 2014-09-18 | Biogen Idec Ma Inc. | Anti-alpha v beta 6 antibodies and uses thereof |
| BR112016002753A2 (pt) * | 2013-08-13 | 2017-11-21 | Sanofi Sa | anticorpos contra o inibidor-1 de ativador de plasminogênio (pai-1) e usos dos mesmos |
| CN106232625B (zh) * | 2013-10-01 | 2020-04-24 | 免疫医疗有限公司 | 治疗和诊断过表达α-V-β-6的癌症的方法 |
| KR102321861B1 (ko) * | 2017-03-10 | 2021-11-05 | 쑤저우 카노바 바이오파마슈티컬 컴퍼니 리미티드 | Il-17a 및 il-17f 모두에 대한 단일클론 항체 및 이의 용도 |
| EP3630844A4 (en) * | 2017-05-30 | 2021-03-03 | Chong Kun Dang Pharmaceutical Corp. | NOVEL ANTI-C-MET ANTIBODY AND USE OF IT |
| US20210363259A1 (en) * | 2017-08-22 | 2021-11-25 | Biogen Ma Inc. | Pharmaceutical compositions and dosage regimens containing anti-alpha(v)beta(6) antibodies |
| GB201814562D0 (en) * | 2018-09-07 | 2018-10-24 | Hummingbird Bioscience Pte Ltd | Vista antigen-binding molecules |
| TWI884192B (zh) | 2019-12-05 | 2025-05-21 | 美商西健公司 | 抗αVβ6抗體及抗體-藥物結合物 |
| EP4518905A1 (en) * | 2022-05-06 | 2025-03-12 | Seagen Inc. | Immunomodulatory antibody-drug conjugates |
-
2020
- 2020-12-04 TW TW109142793A patent/TWI884192B/zh active
- 2020-12-04 IL IL293195A patent/IL293195A/en unknown
- 2020-12-04 CA CA3159414A patent/CA3159414A1/en active Pending
- 2020-12-04 EP EP20897470.9A patent/EP4069297A4/en active Pending
- 2020-12-04 WO PCT/US2020/063390 patent/WO2021113697A1/en not_active Ceased
- 2020-12-04 US US17/112,533 patent/US11827709B2/en active Active
- 2020-12-04 CN CN202080083543.8A patent/CN114828887B/zh active Active
- 2020-12-04 JP JP2022533071A patent/JP7551750B2/ja active Active
- 2020-12-04 TW TW114126218A patent/TWI925717B/zh active
- 2020-12-04 KR KR1020227021011A patent/KR20220110231A/ko active Pending
- 2020-12-04 AU AU2020397070A patent/AU2020397070A1/en active Pending
- 2020-12-04 MX MX2022006132A patent/MX2022006132A/es unknown
- 2020-12-04 BR BR112022009570A patent/BR112022009570A2/pt unknown
-
2023
- 2023-10-18 US US18/489,216 patent/US12268751B2/en active Active
-
2024
- 2024-09-04 JP JP2024151893A patent/JP2024170517A/ja not_active Withdrawn
-
2025
- 2025-03-03 US US19/068,074 patent/US20250242041A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023504187A (ja) | 2023-02-01 |
| TWI884192B (zh) | 2025-05-21 |
| JP7551750B2 (ja) | 2024-09-17 |
| TW202134281A (zh) | 2021-09-16 |
| US11827709B2 (en) | 2023-11-28 |
| KR20220110231A (ko) | 2022-08-05 |
| BR112022009570A2 (pt) | 2022-08-02 |
| IL293195A (en) | 2022-07-01 |
| EP4069297A1 (en) | 2022-10-12 |
| US20250242041A1 (en) | 2025-07-31 |
| US12268751B2 (en) | 2025-04-08 |
| TWI925717B (zh) | 2026-05-11 |
| US20240076383A1 (en) | 2024-03-07 |
| WO2021113697A1 (en) | 2021-06-10 |
| AU2020397070A1 (en) | 2022-07-14 |
| CN114828887A (zh) | 2022-07-29 |
| CN114828887B (zh) | 2026-05-01 |
| EP4069297A4 (en) | 2024-02-14 |
| CA3159414A1 (en) | 2021-06-10 |
| US20210198367A1 (en) | 2021-07-01 |
| JP2024170517A (ja) | 2024-12-10 |
| TW202617777A (zh) | 2026-05-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR120147A1 (es) | Anticuerpos anti-pd-l1 y conjugados anticuerpo-fármaco | |
| CL2018003758A1 (es) | Conjugados anticuerpo anti-dll3-fármaco y métodos de uso. (divisional solicitud 201800458) | |
| MX2021009138A (es) | Anticuerpos anti-cd228 y conjugados de anticuerpo-farmaco. | |
| MX2020012788A (es) | Conjugados de farmaco y anticuerpo anti-sez6 y metodos de uso. | |
| CL2018001722A1 (es) | Nuevos anticuerpos anti-mfi2 y métodos de uso (divisional solicitud 201700506) | |
| MX2019010156A (es) | Proteínas multiespecíficas de unión de direccionamiento a anhidrasa carbónica 9 (caix), anoctamina-1 (ano1), mesotelina, antígeno de superficie celular de trofoblasto (trop2), antígeno carcinoembrionario (cea) o claudina-18.2. | |
| CO2020010956A2 (es) | Composiciones y métodos para el tratamiento del cáncer y de trastornos inmunitarios usando bacterias de veillonella | |
| MX2021002970A (es) | Proteinas de union a nkg2d, cd16 y un antigeno asociado a tumor. | |
| MX2019010040A (es) | Composiciones y métodos para el tratamiento del cáncer. | |
| MX2017014955A (es) | Agentes de union a inmunorreceptor de celulas t con dominios ig y motivo de inhibicion basado en tirosina de inmunorreceptor (tigit) y usos de los mismos. | |
| MX2018005315A (es) | Composiciones y metodos para el tratamiento del cancer. | |
| MX2018006249A (es) | Nuevos anticuerpos anti-emr2 y metodos de uso. | |
| TW202617777A (zh) | 抗αVβ6抗體及抗體-藥物結合物 | |
| CO2022007924A2 (es) | Conjugados de anticuerpo y fármaco de eribulina anti-mesotelina y métodos de uso | |
| EA202091161A1 (ru) | Конъюгаты антител против cd22 с майтанзином, их комбинации и способы применения | |
| EA202191257A1 (ru) | Противораковая терапия на основе иммуноцитов, связывающих liv1 | |
| MX2018007818A (es) | Anticuerpos dirigidos contra upk1b novedosos y metodos para su uso. | |
| CO2019000753A2 (es) | Métodos para tratar el cáncer de próstata | |
| MX2018007817A (es) | Nuevos anticuerpos anti-mmp16 y metodos para su uso. | |
| AR104987A1 (es) | Inmunoconjugados anticuerpo-fármaco unidos por enlazadores no peptídicos | |
| MX2023001143A (es) | Anticuerpos anti-cd228 y conjugados de anticuerpos-farmacos. | |
| MX2020010110A (es) | Conjugados de farmacos de agentes de union monoclonales de cmet, y usos de los mismos. | |
| MX2018013484A (es) | Nuevos anticuerpos anti-tnfrsf21 y modos de uso. | |
| MX2021013117A (es) | Composiciones y metodos para el tratamiento del cancer. | |
| EA202192173A1 (ru) | Анти-cd228 антитела и конъюгаты антитело-лекарственное средство |